Margaret I. Johnston, Ph.D., and Anthony S. Fauci, M.D.
Although a number of methods of preventing infection with the human immunodeficiency virus (HIV) have proven effective to varying degrees, it is generally agreed that a safe and effective vaccine against HIV infection would be a critical component of a highly effective prevention toolkit for controlling and ultimately ending the global AIDS pandemic. For nearly all important pathogens for which effective vaccines have been developed, such as smallpox, measles, and poliovirus, there exists a natural model of protection: the immune response to the pathogen ultimately clears the microbe from the body and confers durable protection against reinfection. Under these circumstances, the human immune system has already provided us with proof of the concept that it can generate a protective response. This fact has led to a fundamental tenet of vaccinology: the best way to develop an effective vaccine is to design a candidate that mimics infection and induces responses akin to natural immunit
Although a number of methods of preventing infection with the human immunodeficiency virus (HIV) have proven effective to varying degrees, it is generally agreed that a safe and effective vaccine against HIV infection would be a critical component of a highly effective prevention toolkit for controlling and ultimately ending the global AIDS pandemic. For nearly all important pathogens for which effective vaccines have been developed, such as smallpox, measles, and poliovirus, there exists a natural model of protection: the immune response to the pathogen ultimately clears the microbe from the body and confers durable protection against reinfection. Under these circumstances, the human immune system has already provided us with proof of the concept that it can generate a protective response. This fact has led to a fundamental tenet of vaccinology: the best way to develop an effective vaccine is to design a candidate that mimics infection and induces responses akin to natural immunit
Unfortunately, this lesson does not apply to HIV infection. We have known since the mid-1980s that the body's natural immune response to HIV infection is completely inadequate. A “natural” immune response that might adequately control HIV infection does not occur at all, occurs too rarely, is too weak, or is too slow to begin. Thus, a key goal for an effective HIV vaccine is to induce in the recipient a response that differs qualitatively, quantitatively, or both from that induced by natural infection — a response that has been referred to as “unnatural immunity.”
